CRDMO Syngene: Your partner in building a healthier world
With a 30-year history in biologics and pharmaceutical services, CRDMO Syngene is now primed to offer integrated drug discovery and development services across modalities. Discover why we are the preferred partner to more than 450 companies around the globe for drug substances, drug products, clinical development, and commercial manufacturing.
CROs at the high table of drug discovery
Find out how offshoring has reached an inflection point as CROs turn risk-sharing partners in discovery research.
CMOs bask in pill promise
With sponsors having more oral solid dosage (OSD) products in their pipelines, CMOs anticipate an increasing trend in OSD outsourcing. Find out the criteria to choose the right CMO for OSD outsourcing.
Pharma 4.0: Taking CDMO factories by storm
Contract development manufacturing firms are ramping up the adoption of Pharma 4.0 technologies as regulators and customers increasingly seek transparency and integrity in manufacturing data.
New modalities hog the limelight
Explore how Cell and Gene, mRNA, Bispecifics, and ADCs are turning the tide as CDMOs see service demand for these therapies soar.
Bioanalytical outsourcing soars as drugs grow more complex
Outsourcing of bioanalytical lab services is set for explosive growth as the increasingly complex nature of modern-day therapeutics makes partnerships with CROs indispensable.
Net-zero pledge: CDMOs go greener
A number of CDMOs are accelerating their environmental drive as sustainability goals become one of the most urgent business strategies facing pharma companies today.
Powering up antibody-drug conjugates with PROTACS
Read this White Paper on the ADC alternative that is capturing scientists’ imagination – antibody-linked PROTACs and the impact it could have in oncology, neurology, virology, and agriculture.
Innovation at Syngene: Translatable models for improving cancer research
Syngene has developed orthotopic models validated against the standard of care and tumor models with 3D culture, which can help improve translatability and clinical relevance in cancer research.
pDNA and mRNA manufacturing in the age of Precision Therapies: The role of CDMOs
Challenges in pDNA manufacturing and why CDMOs are best suited for supplying pDNA for Precision Therapies.